trial

Mechanistic Clinical Trial of Individualized tDCS for Hallucinations in Schizophrenia

NCTId NCT04248010
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Withdrawn
Enrollment 0 (actual)
Sponsored by Columbia University
Primary completion 2025-06-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2022-12
Primary completion
2025-06-01
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
neuroConn DC-Stimulator MRSoterix MxN HD-tES

Sponsors

Columbia UniversityLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
0
Phase
NA
Primary Completion Date
2025-06-01
Status
WITHDRAWN
relationships
The graph out of here
drug
neuroConn DC-Stimulator MR
drug
Soterix MxN HD-tES
drug
lead_sponsor
Columbia University
company
indication
Schizophrenia and Related Disorders
indication
Schizophrenia
indication